Characteristics of the patients included an average age of 65 years, 55% were female, the average body mass index was 38, and the mean left ventricular ejection fraction was 61% (the minimum for trial entry was 50%)
Finnish Diabetes Prevention Study Group
While BPC-157 is not a miracle, it has shown promising results in areas like: Accelerated healing of tendons, muscles, nerves, and ligaments Reduced inflammation and pain Gut lining repair, helpful in conditions like leaky gut or IBD Enhanced recovery from injury or surgery Because it supports both systemic healing and targeted gastrointestinal repair, BPC-157 appeals to a broad range of individuals from athletes recovering from injuries to those managing chronic digestive conditions
If youre unsure about a vials viability, call us well help you decide whether to discard it or continue safely.
If oral tirzepatide is approved only for type 2 diabetes (like oral semaglutide initially was), insurance coverage for obesity will be limited